{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T05:28:31Z","timestamp":1781069311288,"version":"3.54.1"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.lungcan.2024.107968","type":"journal-article","created":{"date-parts":[[2024,9,30]],"date-time":"2024-09-30T05:40:31Z","timestamp":1727674831000},"page":"107968","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC)"],"prefix":"10.1016","volume":"197","author":[{"given":"Sai-Hong","family":"Ou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Kilvert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Candlish","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Polli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Despina","family":"Thomaidou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Le","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7153","key":"10.1016\/j.lungcan.2024.107968_b0005","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/nature05945","article-title":"Identification of the transforming EML4\u2013ALK fusion gene in non-small-cell lung cancer","volume":"448","author":"Soda","year":"2007","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.lungcan.2024.107968_b0010","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1097\/JTO.0b013e3181c4dedb","article-title":"ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer","volume":"4","author":"Solomon","year":"2009","journal-title":"J. Thorac. Oncol."},{"issue":"10","key":"10.1016\/j.lungcan.2024.107968_b0015","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1016\/j.jtho.2018.06.012","article-title":"Results of PROFILE 1029, a phase III comparison of first-line crizotinib versus chemotherapy in east asian patients with ALK-Positive advanced non\u2013Small cell lung Cancer","volume":"13","author":"Wu","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"22","key":"10.1016\/j.lungcan.2024.107968_b0020","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1200\/JCO.2017.77.4794","article-title":"Final overall survival analysis from a study comparing first-line crizotinib versus chemotherapy in ALK-mutation-positive non-small-cell lung cancer (PROFILE 1014)","volume":"36","author":"Solomon","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"10072","key":"10.1016\/j.lungcan.2024.107968_b0025","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0140-6736(17)30123-X","article-title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study","volume":"389","author":"Soria","year":"2017","journal-title":"Lancet"},{"issue":"10089","key":"10.1016\/j.lungcan.2024.107968_b0030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(17)30565-2","article-title":"Alectinib versus crizotinib in patients with ALK-positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial","volume":"390","author":"Hida","year":"2017","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.lungcan.2024.107968_b0035","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S2213-2600(19)30053-0","article-title":"Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study","volume":"7","author":"Zhou","year":"2019","journal-title":"Lancet Respir. Med."},{"issue":"7","key":"10.1016\/j.lungcan.2024.107968_b0040","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1016\/j.jtho.2019.03.007","article-title":"Updated efficacy and safety data and impact of the EML4-ALK fusion variant on the efficacy of alectinib in untreated ALK-positive advanced Non-Small cell lung cancer in the global phase III ALEX study","volume":"14","author":"Camidge","year":"2019","journal-title":"J. Thorac. Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2024.107968_b0045","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1056\/NEJMoa1810171","article-title":"Brigatinib versus crizotinib in ALK-positive non\u2013small-cell lung cancer (ALTA-1L)","volume":"379","author":"Camidge","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lungcan.2024.107968_b0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2021.3523","article-title":"Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase\u2212 positive non-small cell lung cancer: a randomized clinical trial","author":"Horn","year":"2021","journal-title":"JAMA Oncol."},{"issue":"21","key":"10.1016\/j.lungcan.2024.107968_b0055","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa2027187","article-title":"First-line lorlatinib or crizotinib in advanced ALK-positive lung cancer","volume":"383","author":"Shaw","year":"2020","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.lungcan.2024.107968_b0060","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.lungcan.2024.107968_b0065","unstructured":"(FDA) FaDA. FDA approves lorlatinib for metastatic ALK-positive NSCLC. (Updated: March 4, 2021) Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-lorlatinib-metastatic-alk-positive-nsclc. Accessed: December 22, 2021."},{"key":"10.1016\/j.lungcan.2024.107968_b0070","unstructured":"(FDA) FaDA. Alectinib approved for (ALK) positive metastatic non-small cell lung cancer (NSCLC). (Updated: November 7, 2017) Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/alectinib-approved-alk-positive-metastatic-non-small-cell-lung-cancer-nsclc. Accessed: December 22, 2021."},{"key":"10.1016\/j.lungcan.2024.107968_b0075","unstructured":"(FDA) FaDA. FDA approves brigatinib for ALK-positive metastatic NSCLC. (Updated: May 26, 2020) Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-brigatinib-alk-positive-metastatic-nsclc. Accessed: December 21, 2021."},{"key":"10.1016\/j.lungcan.2024.107968_b0080","unstructured":"(FDA) FaDA. FDA Approves Crizotinib Capsules. (Updated: March 11, 2016). Accessed: December 21, 2021."},{"key":"10.1016\/j.lungcan.2024.107968_b0085","unstructured":"(FDA) FaDA. FDA broadens ceritinib indication to previously untreated ALK-positive metastatics NSCLC. (Updated: July 25, 2017) Available at: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-broadens-ceritinib-indication-previously-untreated-alk-positive-metastatic-nsclc. Accessed: December 22, 2021."},{"key":"10.1016\/j.lungcan.2024.107968_b0090","unstructured":"NCCN. Clinical practice guidelines in oncology: non-small cell lung cancer. V4.: National Comprehensive Cancer Network, 2021."},{"issue":"4","key":"10.1016\/j.lungcan.2024.107968_b0095","first-page":"354","article-title":"Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study","volume":"11","author":"Solomon","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2024.107968_b0100","unstructured":"T. Baisamut, Alectinib vs crizotinib in Asian patients with treatment-na\u00efve advanced ALK+ non-small cell lung cancer: 5-year update from the Phase 3 ALESIA study. ESMO2022."},{"key":"10.1016\/j.lungcan.2024.107968_b0105","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.lungcan.2019.11.025","article-title":"Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer","volume":"139","author":"Nakagawa","year":"2020","journal-title":"Lung Cancer"},{"issue":"12","key":"10.1016\/j.lungcan.2024.107968_b0110","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.jtho.2021.07.035","article-title":"Brigatinib versus crizotinib in ALK inhibitor\u2013naive advanced ALK-positive NSCLC: final results of phase 3 ALTA-1L trial","volume":"16","author":"Camidge","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"11","key":"10.1016\/j.lungcan.2024.107968_b0115","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1001\/jamaoncol.2021.3523","article-title":"Ensartinib vs crizotinib for patients with anaplastic lymphoma kinase\u2212positive non-small cell lung cancer a randomized clinical trial","volume":"7","author":"Horn","year":"2021","journal-title":"JAMA Oncol."},{"issue":"6","key":"10.1016\/j.lungcan.2024.107968_b0120","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"Bucher","year":"1997","journal-title":"J. Clin. Epidemiol."},{"key":"10.1016\/j.lungcan.2024.107968_b0125","unstructured":"R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. 2019. Available at: https:\/\/www.R-project.org\/. Accessed: 16 September 2019."},{"key":"10.1016\/j.lungcan.2024.107968_b0130","unstructured":"G. Van Valkenhoef, J. Kuiper, gemtc: Network Meta-Analysis Using Bayesian Methods. 2016. Available at: https:\/\/CRAN.R-project.org\/package=gemtc. Accessed: 13th September 2017."},{"key":"10.1016\/j.lungcan.2024.107968_b0135","series-title":"NICE DSU Technical Support Document 1: Introduction to evidence synthesis for decision making","first-page":"1","author":"Dias","year":"2011"},{"issue":"9","key":"10.1016\/j.lungcan.2024.107968_b0140","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1471-2288-12-9","article-title":"Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves","volume":"12","author":"Guyot","year":"2012","journal-title":"BMC Med. Res. Method."},{"issue":"15","key":"10.1016\/j.lungcan.2024.107968_b0145","doi-asserted-by":"crossref","first-page":"3704","DOI":"10.3390\/cancers13153704","article-title":"Comparative efficacy and safety of lorlatinib and alectinib for ALK-rearrangement positive advanced non-small cell lung cancer in asian and non-Asian patients: a systematic review and network meta-analysis","volume":"13","author":"Ando","year":"2021","journal-title":"Cancers"},{"issue":"8","key":"10.1016\/j.lungcan.2024.107968_b0150","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.3390\/cancers13081966","article-title":"Systematic review and network meta-analysis of anaplastic lymphoma kinase (ALK) inhibitors for treatment-na\u00efve ALK-positive lung cancer","volume":"13","author":"Chuang","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.lungcan.2024.107968_b0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105931","article-title":"A Bayesian network meta-analysis regarding the comparative efficacy of therapeutics for ALK-positive, brain metastatic non-small cell lung cancer","author":"Zhao","year":"2021","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.lungcan.2024.107968_b0160","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1186\/s12885-021-08977-0","article-title":"Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with ALK-rearranged: a meta-analysis of clinical trials","volume":"21","author":"Ma","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.lungcan.2024.107968_b0165","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.754768","article-title":"Efficacy and safety of first-line treatment strategies for anaplastic lymphoma kinase-positive non-small cell lung cancer: a bayesian network meta-analysis","volume":"11","author":"Peng","year":"2021","journal-title":"Front. Oncol."},{"key":"10.1016\/j.lungcan.2024.107968_b0170","article-title":"Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor\u2013naive\/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis","volume":"1\u201310","author":"Wang","year":"2021","journal-title":"J. Chemother."},{"key":"10.1016\/j.lungcan.2024.107968_b0175","article-title":"Front-line treatment for advanced non-small-cell lung cancer and ALK fusion: a network meta-analysis","volume":"14","author":"Wen","year":"2022","journal-title":"Therapeutic Adv. Med. Oncol."},{"issue":"7","key":"10.1016\/j.lungcan.2024.107968_b0180","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.jtho.2019.03.002","article-title":"Efficacy and safety of ceritinib (450 mg\/d or 600 mg\/d) with food versus 750-mg\/d fasted in patients with ALK receptor tyrosine kinase (ALK)\u2013positive NSCLC: primary efficacy results from the ASCEND-8 study","volume":"14","author":"Cho","year":"2019","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.lungcan.2024.107968_b0185","unstructured":"J. Gregory, H. Kilvert, T. Williams, et al., World Conference on Lung Cancer, poster presentation; Lorlatinib in First Line Treatment of Patients with ALK+ Non-small-cell Lung Cancer: a Network Meta-analysis. 2021."},{"key":"10.1016\/j.lungcan.2024.107968_b0190","unstructured":"S.-H. Ou, H. Kilvert, J. Candlish, B. Lee, First-line Lorlatinib in Patients with Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer: Updated Network Meta-Analysis (NMA) and Review of 10 NMAs. World Conference on Lung Cancer (Singapore) 2023."},{"issue":"19","key":"10.1016\/j.lungcan.2024.107968_b0195","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10194376","article-title":"First-line anaplastic lymphoma kinase (ALK) inhibitors for ALK-positive lung cancer in Asian populations: systematic review and network meta-analysis","volume":"10","author":"Wu","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.lungcan.2024.107968_b0200","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1111\/1759-7714.14824","article-title":"Efficacy and safety of anaplastic lymphoma kinase inhibitors for non\u2013small cell lung cancer: a systematic review and network meta-analysis","volume":"14","author":"Peng","year":"2023","journal-title":"Thoracic Cancer."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224005026?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0169500224005026?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T07:05:20Z","timestamp":1731999920000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0169500224005026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":40,"alternative-id":["S0169500224005026"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107968","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC)","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2024.107968","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107968"}}